

**Compounds interfering with Embryonic Lethal Abnormal Vision (ELAV) protein–RNA complexes: an avenue for discovering new drugs**

Rita Nasti<sup>†</sup>, Daniela Rossi<sup>†</sup>, Marialaura Amadio<sup>‡</sup>, Alessia Pascale<sup>‡</sup>, M. Yagiz Unver<sup>§</sup>, Anna K.H Hirsch<sup>§</sup>, Simona Collina<sup>†\*</sup>

<sup>†</sup> Department of Drug Science, Medicinal Chemistry Division, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy

<sup>‡</sup> Department of Drug Science, Pharmacological Division, University of Pavia, Via Taramelli 14, 27100 Pavia, Italy

<sup>§</sup> Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, NL-9747 AG Groningen, The Netherlands


\*Corresponding author: Prof. Simona Collina, e-mail: [simona.collina@unipv.it](mailto:simona.collina@unipv.it), phone+39 0382987379

**Supporting information**


## Predicted binding mode of compounds.

These binding modes are the result of a docking run using the FlexX docking module with 30 poses and represent the top-scoring pose after HYDE scoring with SEESAR and careful visual inspection to exclude poses with significant inter- or intra-molecular clash terms or unfavorable conformations. The figures were generated with PoseView as implemented in the LeadIT suite.


### Compounds 1–3






### Compounds 9–11






## Compound 13



## Compounds 14–19





## Compounds 20–22

